Navigation Links
Venaxis' APPY1 Test Passes Futility Analysis in Pivotal Clinical Study
Date:7/15/2013

on our commercial milestones in Europe, where we are preparing to initiate economic outcomes studies at leading hospitals.  Importantly, with our recent financing, we have sufficient capital to achieve major regulatory and commercial milestones.  While we remain prudent with the use of cash, we see no financial obstacles to reaching these significant value inflection points."

Venaxis strengthened its financial position with an additional $14.4 million in gross proceeds from a May public offering led by Piper Jaffray & Company.  The Company currently estimates cash, cash equivalents, and short-term investments to be approximately $20 million at the close of the second quarter 2013, which will be reflected in the Company's Form 10-Q to be filed in the coming weeks.  

Don Hurd, Senior Vice President and Chief Commercial Officer of Venaxis, stated, "We remain on track for a full-scale European launch for the APPY1 Test beginning in the fourth quarter of this year.  We currently have four market development agreements in place and we are in the final process of selecting partners in additional target countries, including Germany, the UK, and France.  In terms of our existing partner agreements, we are initiating and expect to complete several outcome studies by the end of the third quarter 2013 and anticipate leveraging robust data from those studies to demonstrate objectively the clinical and economic value of using the APPY1 Test in the hospital emergency room. We remain focused on laying a solid foundation as we continue onto full-scale commercialization of APPY1 in Europe and advance to commercialization in the United States."

Conference Call Information
The Company has scheduled its quarterly conference call and webcast f
'/>"/>

SOURCE Venaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Venaxis Announces Pricing of Offering of Common Stock and Warrants
2. Venaxis Executes First Commercial Development Agreement and Receives Purchase Order from EMELCA Bioscience for Initial EU Launch
3. YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group
4. Eastern Clinical Trials Russia CRO Passes EMA Inspection
5. Legendary Author And Screenwriter Nora Ephron Passes Away At 71; Solar Cigarette Pays Tribute To Such A Rare Talent
6. Butamax Early Adopters Group surpasses capacity targets with addition of Big River; Membership represents 11 production facilities and nearly 900 million gallons of ethanol capacity
7. Free Expo-Hall Passes for ATA 2012
8. Accuray Surpasses 600 Installations Globally
9. Unisense FertiliTech to Present Large Scale Time-lapse Data Analysis to Improve IVF Treatment
10. New Approaches in Immunogenicity Assessment Using the New SQiDlite™ System: Case Study Analysis, New Life Science Webinar Hosted by Xtalks
11. Rigaku Publishes New Application Note for Analysis of ULSD Per ISO 13032
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... The first part of the session on “Best ... Studies” will cover comprehensive clinical support in early phase ... R&D costs and declining industry success in getting products ... collected in early Phase I/IIa study data to make ... development. , Next, the presenters will examine steps to ...
(Date:7/24/2014)... As part of the long-term strategic approach, ... region during 2014 with potential global expansion. , "We ... DZS to manage our clinical trials globally and in ... R&D and President of SBI pharmaceuticals MENA, Dr. Riyadh ... a focus on utilizing eClinical software and flexible team ...
(Date:7/23/2014)... 2014  Sangamo BioSciences, Inc. (NASDAQ: SGMO ... and accomplishments. For the second quarter ... loss of $7.0 million, or $0.10 per share, compared ... per share, for the same period in 2013. As ... equivalents, marketable securities and interest receivable of $236.7 million. ...
(Date:7/23/2014)... , July 23, 2014 /PRNewswire-iReach/ -- Think Drinks are ... for the long term. They are the first functional ... sustained energy as an alternative to the temporary fix ... on Indiegogo on July 29, 2014, with hopes to ... Photo - http://photos.prnewswire.com/prnh/20140723/129697 ...
Breaking Biology Technology:Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 3Sangamo BioSciences Reports Second Quarter 2014 Financial Results 4Sangamo BioSciences Reports Second Quarter 2014 Financial Results 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 6Sangamo BioSciences Reports Second Quarter 2014 Financial Results 7Sangamo BioSciences Reports Second Quarter 2014 Financial Results 8Sangamo BioSciences Reports Second Quarter 2014 Financial Results 9truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2
... June 14 aTyr Pharma, Inc. today announced ... joined the company as its Senior Vice President of ... help to advance aTyr Pharma,s portfolio of resectin-based therapeutics. ... derived from aminoacyl tRNA synthetases, and have activities relevant ...
... June 14 Data presented at the ... , highlights the impact of febrile neutropenia (FN) on ... NHL study showed that unplanned hospitalisations, delays in chemotherapy ... dose intensity (RDI) of chemotherapy were more frequent in ...
... ... on centralizing information to meet researchers, needs. , ... (PRWEB) -- STEMCELL Technologies Inc has just launched its next ... to meet researchers, needs., , ,The site has been completely redesigned to provide specialized sections ...
Cached Biology Technology:aTyr Pharma Appoints Catharine E. Johnson As Senior Vice President of Business Development 2aTyr Pharma Appoints Catharine E. Johnson As Senior Vice President of Business Development 3New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 2New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 3New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 4New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 5New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 6New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 7New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 8New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 9STEMCELL Technologies Inc Launches New Website 2
(Date:7/24/2014)... 2014(BRONX, NY)Researchers at Albert Einstein College of Medicine ... The Michael J. Fox Foundation for Parkinson,s Research to ... Parkinson,s disease. This drug discovery project will test chemical ... of developing a drug that acts on an underlying ... for Parkinson,s help many people manage their symptoms, we ...
(Date:7/24/2014)... which have similar counterparts in humans, affect the connections ... signals into the hippocampus, an area of the brain ... the creation of memories. The results of the study ... , Brain function depends on the active communication between ... are woven together into a dense network where they ...
(Date:7/24/2014)... is a hotspot of biodiversity and one of the ... toads) in the world. However, current levels of diversity ... has been an increase in the description of new ... of molecular techniques and availability of samples for DNA ... samples for molecular and morphological analysis, researchers from the ...
Breaking Biology News(10 mins):Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3A protein couple controls flow of information into the brain's memory center 2A protein couple controls flow of information into the brain's memory center 3A protein couple controls flow of information into the brain's memory center 4A tiny new species of frog from Brazil with a heroic name 2
... members at the University of South Florida in Tampa have ... of Science (AAAS). Election as an AAAS Fellow is an ... This year 388 members have been awarded this honor by ... advance science or its applications. With six Fellows, ...
... so do portion size and the amount of food actually ... people are to this plate-size bias? New research by the ... children respond differently to environmental cues, such as plate size, ... breakfast behaviors of kids, ages 6 to 10, in a ...
... a variety of methods to spread their seeds, including gravity, ... of the mushrooms, whose spores also need to be strewn ... have long thought that the spores produced by a mushroom,s ... problem with that notion, said Emilie Dressaire, a professor of ...
Cached Biology News:AAAS and the University of South Florida announce 2013 Fellows 2AAAS and the University of South Florida announce 2013 Fellows 3AAAS and the University of South Florida announce 2013 Fellows 4AAAS and the University of South Florida announce 2013 Fellows 5Extrovert and introvert children are not equally influenced by plate size 2The mushrooms, my friend, are blowing in the wind... 2
... your microarray data using Asuragens bioinformatics ... need from consultation to extensive data ... date methods. Utilize our expertise in ... Service or from your own microarray ...
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ...
Formula variant: With macro- and micronutrients. Physical Form: powder Suitab tst: plant cell culture tested...
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
Biology Products: